Spasmolytic polypeptide‐expressing metaplasia associated with higher expressions of miR‐21, 155, and 223 can be regressed by Helicobacter pylori eradication in the gastric cancer familial relatives
Open Access
- 16 April 2019
- journal article
- research article
- Published by Wiley in Helicobacter
- Vol. 24 (3) , e12578
Abstract
Background and aims: Spasmolytic polypeptide‐expressing metaplasia (SPEM) is a preneoplastic gastric cancer lesion related to epigenetic microRNA (miRNA) expression. This study elucidated whether Helicobacter pylori‐infected first‐degree relatives of patients with gastric cancer (GCF) are susceptible to have SPEM and correlated with miR‐21, 155, and 223 expressions. We also validated whether SPEM and these miRNAs can be regressed after H pylori eradication.Methods: We prospectively enrolled 148 GCF and 148 nonulcer dyspepsia (NUD) subjects without gastric cancer familial history as controls. Each case had received a panendoscopy to determine H pylori status and gastric histology, including SPEM. The cases with SPEM were followed after H pylori eradication to determine SPEM regression. The total RNA was extracted to analyze tissues miR‐21, 155, and 223 before and after eradication.Results: GCF subjects had a higher prevalence of H pylori infection (73% vs 32%) and SPEM (42% vs 14%, P < 0.01) than controls. The tissue miR‐21, 155, and 223 in antrum were higher in cases with SPEM than in those without SPEM (P <= 0.05). There was similar SPEM reversibility after H pylori eradication between GCF subjects and controls (72% vs 69%, P = 0.852). In the SPEM regressed cases, tissue miR‐21, 155, and 223 decreased after H pylori eradication (P < 0.05).Conclusion: The H pylori‐infected GCF subjects were prone to have SPEM with higher tissues miR‐21, 155, and 223 expressions. H pylori eradication can result in a 70% SPEM regression, accompanied by a decline in miR‐21, 155, and 233 expression levels.Keywords
Funding Information
- MOST (MOST, 107-2314-B-006-021-MY3, MOST 104-2314-B-006-025-MY3, MOST 106-2314-B-006-020-MY2)
This publication has 39 references indexed in Scilit:
- Pyloric metaplasia, pseudopyloric metaplasia, ulcer‐associated cell lineage and spasmolytic polypeptide‐expressing metaplasia: reparative lineages in the gastrointestinal mucosaThe Journal of Pathology, 2018
- Gastric cancer: epidemiology, prevention, classification, and treatmentCancer Management and Research, 2018
- Genomic single nucleotide polymorphisms in the offspring of gastric cancer patients predispose to spasmolytic polypeptide-expressing metaplasia after H. pylori infectionJournal of Biomedical Science, 2015
- A CagA‐independent cluster of antigens related to the risk of noncardia gastric cancer: Associations between Helicobacter pylori antibodies and gastric adenocarcinoma explored by multiplex serologyInternational Journal of Cancer, 2013
- Risk Factors of Atrophic Gastritis and Intestinal Metaplasia in First-Degree Relatives of Gastric Cancer Patients Compared with Age-Sex Matched ControlsJournal of Cancer Prevention, 2013
- Spasmolytic Polypeptide-Expressing Metaplasia and Intestinal Metaplasia: Time for Reevaluation of Metaplasias and the Origins of Gastric CancerGastroenterology, 2010
- Current understanding of SPEM and its standing in the preneoplastic processGastric Cancer, 2009
- Family history and the risk of gastric cancerBritish Journal of Cancer, 2009
- Prevalence and Risk Factors of Atrophic Gastritis and Intestinal Metaplasia in a Korean Population Without Significant Gastroduodenal DiseaseHelicobacter, 2008
- Family history and the risk of stomach and colorectal cancerCancer, 1992